Marc Goodman
Stock Analyst at Leerink Partners
(3.67)
# 1,402
Out of 5,113 analysts
96
Total ratings
57.14%
Success rate
29.79%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $186.27 | +10.06% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $2.03 | +294.09% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $18.60 | +61.29% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.55 | +222.58% | 1 | Nov 17, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $21.58 | -14.27% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $21.20 | +60.38% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $12.09 | +313.74% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.74 | -32.16% | 5 | May 7, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $3.96 | -74.75% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $17.59 | +81.92% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $165.91 | -84.93% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.58 | +131.70% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $4.65 | +330.11% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $137.11 | -16.13% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $176.34 | +75.80% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $41.77 | +10.13% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $25.69 | -18.26% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $163.74 | +28.25% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.38 | +195.86% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $34.73 | -22.26% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.40 | +177.78% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $629.84 | -57.13% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $222.55 | -56.86% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.61 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $108.91 | -38.48% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $13.65 | +617.95% | 7 | Oct 5, 2017 |
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $186.27
Upside: +10.06%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $2.03
Upside: +294.09%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $18.60
Upside: +61.29%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.55
Upside: +222.58%
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $21.58
Upside: -14.27%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $21.20
Upside: +60.38%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $12.09
Upside: +313.74%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.74
Upside: -32.16%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $3.96
Upside: -74.75%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $17.59
Upside: +81.92%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $165.91
Upside: -84.93%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $21.58
Upside: +131.70%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.65
Upside: +330.11%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $137.11
Upside: -16.13%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $176.34
Upside: +75.80%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $41.77
Upside: +10.13%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $25.69
Upside: -18.26%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $163.74
Upside: +28.25%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.38
Upside: +195.86%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $34.73
Upside: -22.26%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.40
Upside: +177.78%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $629.84
Upside: -57.13%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $222.55
Upside: -56.86%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $54.61
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $108.91
Upside: -38.48%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $13.65
Upside: +617.95%